Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | LONP1 | P36776 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25963869 | 1.00 | KDM4E (0.42) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL19261469 | 1.00 | KDM4E (0.42) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL20051941 | 1.00 | KDM4E (0.42) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL21515801 | 0.98 | KDM4E (0.41) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL21715644 | 0.98 | KDM4E (0.40) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL25430708 | 0.97 | KDM4E (0.40) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL26874335 | 0.97 | KDM4E (0.40) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL26078436 | 0.97 | KDM4E (0.40) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL26078416 | 0.95 | KDM4E (0.38) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL29786217 | 0.86 | CYP2D6 (0.38) | KDM4ECYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11178871-B2 | Herbicidal pyrimidine compounds | BASF SE (DE) | 2021-11-23 | — | — | US | disclosed |
| US-10683277-B2 | Triazole derivatives as P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190159453-A1 | HERBICIDAL PYRIMIDINE COMPOUNDS | BASF SE (DE) | 2019-05-30 | — | — | US | disclosed |
| US-9725425-B1 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683277-B2 | Triazole derivatives as P2Y14 receptor antagonists | GPR119, P2RY14, P2RY4 | KDM4E 4210/4885CYP2D6 1262/4885CYP19A1 535/4885 |
| US-11178871-B2 | Herbicidal pyrimidine compounds | DPYD, TYMP, TYMS | KDM4E 2747/4885CYP2D6 196/4885CYP19A1 1266/4885 |
| US-20190159453-A1 | HERBICIDAL PYRIMIDINE COMPOUNDS | DPYD, TYMP, TYMS | KDM4E 2747/4885CYP2D6 196/4885CYP19A1 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.